お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
956201

世界の癌ワクチン市場規模調査:種類別、技術別、適応別、エンドユーザー別、および地域別予測:2020~2027年

Global Cancer Vaccines Market Size study, by Type, by Technology, by Indication, by End-User and Regional Forecasts 2020-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
世界の癌ワクチン市場規模調査:種類別、技術別、適応別、エンドユーザー別、および地域別予測:2020~2027年
出版日: 2020年08月28日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の癌ワクチンの市場規模は2019年に約42億米ドルと評価されており、予測期間の2020~2027年には12.6%を超える健全な成長率で成長すると予測されています。

癌ワクチンは免疫療法の一種であり、生物学的応答修飾因子と見なされています。通常、癌治療ワクチンは、細菌やウイルスに対して作用するワクチンとは異なります。癌ワクチンは、患者の体の免疫系を刺激して癌細胞と闘うことができます。これらのワクチンは、病気を予防するのではなく、主に免疫系を強化して、すでに患者の体内ですでに発生している病気を治療することに注力します。

癌ワクチンは一般的に2つのタイプ、すなわち予防用癌ワクチンと治療用癌ワクチンがあります。予防用癌ワクチンは通常、健康な人々の間で癌疾患を予防するために使用されますが、治療用癌ワクチンは、疾患と闘うために患者の免疫反応を強化するために使用されます。

癌患者数の増加、癌治療に対する患者の意識の高まり、および癌ワクチンの開発への投資と政府資金の増加は、予測期間中の市場のCAGRを担う要因となっています。国際癌調査機関(IARC)によると、2018年に世界中で約1,810万件の新規癌症例と960万件の癌による死亡が報告されました。また、世界での癌の罹患動向は、2040年までに、新規症例数が約2,750万件、癌による死亡者数が1,630万人近くに増加すると予測されています。これは、世界的に癌ワクチンに対する需要を高めることになるでしょう。ただし、ワクチンの開発コストの高さ、製品認可に関する厳格な政府の規範とポリシーが、2020年から2027年の予測期間における市場の成長を妨げる要因となっています。

当レポートでは、世界の癌ワクチン市場について調査し、市場の概要とともに、種類別、技術別、適応別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の癌ワクチン市場の定義と範囲

第3章 世界の癌ワクチン市場力学

  • 癌ワクチン市場の影響分析(2018-2027)

第4章 世界の癌ワクチン市場:業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの提言と結論

第5章 種類別世界の癌ワクチン市場

  • 市場のスナップショット
  • 種類別世界の癌ワクチン市場、パフォーマンス-潜在的な分析
  • 種類別世界の癌ワクチン市場の見積と予測:2017-2027年(10億米ドル)
  • 癌ワクチン市場、サブセグメント分析
    • 予防用癌ワクチン
    • 治療用癌ワクチン

第6章 技術別世界の癌ワクチン市場

  • 市場のスナップショット
  • 技術別世界の癌ワクチン市場、パフォーマンス-潜在的な分析
  • 技術別世界の癌ワクチン市場の見積と予測:2017-2027年(10億米ドル)
  • 癌ワクチン市場、サブセグメント分析
    • 樹状細胞(DC)癌ワクチン
    • 組換え癌ワクチン
    • 抗原/アジュバント癌ワクチン
    • ウイルスベクターおよびDNA癌ワクチン

第7章 適応別世界の癌ワクチン市場

  • 市場のスナップショット
  • 適応別世界の癌ワクチン市場、パフォーマンス-潜在的な分析
  • 適応別世界の癌ワクチン市場の見積と予測:2017-2027年(10億米ドル)
  • 癌ワクチン市場、サブセグメント分析
    • 子宮頸癌
    • 前立腺癌
    • その他

第8章 エンドユーザー別世界の癌ワクチン市場

  • 市場のスナップショット
  • エンドユーザー別世界の癌ワクチン市場、パフォーマンス-潜在的な分析
  • エンドユーザー別世界の癌ワクチン市場の見積と予測:2017-2027年(10億米ドル)
  • 癌ワクチン市場、サブセグメント分析
    • 小児
    • 成人

第9章 世界の癌ワクチン市場、地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他

第10章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Advaxis Inc.
    • Amgen Inc.
    • Dynavax Technologies Corporation
    • Generex Biotechnology Corporation
    • GlaxoSmithKline plc (GSK)
    • Immunocellular Therapeutics, Ltd.
    • Merck & Co., Inc.
    • Sanpower Group Co. Ltd.
    • UbiVac, Inc.
    • Vaccinogen, Inc.

第11章 調査プロセス

図表

LIST OF FIGURES

  • FIG 1. Global Cancer Vaccines market, research methodology
  • FIG 2. Global Cancer Vaccines market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Cancer Vaccines market, key trends 2019
  • FIG 5. Global Cancer Vaccines market, growth prospects 2020-2027
  • FIG 6. Global Cancer Vaccines market, porters 5 force model
  • FIG 7. Global Cancer Vaccines market, pest analysis
  • FIG 8. Global Cancer Vaccines market, value chain analysis
  • FIG 9. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 15. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 16. Global Cancer Vaccines market by segment, 2017 & 2027 (USD Billion)
  • FIG 17. Global Cancer Vaccines market, regional snapshot 2017 & 2027
  • FIG 18. North America Cancer Vaccines market 2017 & 2027 (USD Billion)
  • FIG 19. Europe Cancer Vaccines market 2017 & 2027 (USD Billion)
  • FIG 20. Asia-Pacific Cancer Vaccines market 2017 & 2027 (USD Billion)
  • FIG 21. Latin America Cancer Vaccines market 2017 & 2027 (USD Billion)
  • FIG 22. Global Cancer Vaccines market, company market share analysis (2019)
目次

Title:
Global Cancer Vaccines Market Size study, by Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), by Indication (Cervical Cancer, Prostate Cancer, Others), by End-User (Pediatrics, Adults) and Regional Forecasts 2020-2027.

Global Cancer Vaccines Market is valued at approximately USD 4.2 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 12.6% over the forecast period 2020-2027. Cancer vaccines are a form of immunotherapy which is considered as a biological response modifier. Usually, cancer treatment vaccines are distinct from the vaccines that work against bacteria and viruses. Cancer vaccines can stimulate the immune system of the patient's body to fight against cancer cells. Rather than preventing disease, these vaccines are primarily focused to boost the immune systems to medicate a disease that already occurred in the patient's body. The cancer vaccines are generally available in two types i.e. preventive cancer vaccines and therapeutic cancer vaccines. Preventive cancer vaccines are typically used to prevent cancer disease among healthy people, whereas therapeutic cancer vaccines are used to strengthen the immune response among patients to fight against the disease. An increase in the number of cancer patients, growing awareness among patients towards cancer therapy, and rising investment and government funding in the development of cancer vaccine are the few factors responsible for the CAGR of the market during the forecast period. According to the International Agency for Research on Cancer (IARC), around 18.1 million new cancer cases and 9.6 million cancer deaths were reported throughout the world in 2018. Also, the global prevalence of cancer is projected to grow to around 27.5 million new cancer cases and nearly 16.3 million cancer deaths by the year 2040. This, in turn, is likely to strengthen the demand for Cancer Vaccines, globally. However, the high development cost of vaccine and stringent government norms & policies on product approval are the few factors impeding the market growth over the forecast period of 2020-2027.

The regional analysis of the global Cancer Vaccines market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the favorable government support for the approval of cancer vaccines, along with the wide presence of market players in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of cancer and improving healthcare infrastructure in the developing nations, such as China and India, are the few factors creating a lucrative opportunity for the growth of the cancer vaccine market in the Asia-Pacific region.

Major market player included in this report are:

Advaxis Inc.

Amgen Inc.

Dynavax Technologies Corporation

Generex Biotechnology Corporation

GlaxoSmithKline plc (GSK)

Immunocellular Therapeutics, Ltd.

Merck & Co., Inc.

Sanpower Group Co. Ltd.

UbiVac, Inc.

Vaccinogen, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

By Technology:

Dendritic Cells (DC) Cancer Vaccines

Recombinant Cancer Vaccines

Antigen/Adjuvant Cancer Vaccines

Viral Vector & DNA Cancer Vaccines

By Indication:

Cervical Cancer

Prostate Cancer

Others

By End-User:

Pediatrics

Adults

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Cancer Vaccines Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Cancer Vaccines Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Cancer Vaccines Market, by Type, 2018-2027 (USD Billion)
    • 1.2.3. Cancer Vaccines Market, by Technology, 2018-2027 (USD Billion)
    • 1.2.4. Cancer Vaccines Market, by Indication, 2018-2027 (USD Billion)
    • 1.2.5. Cancer Vaccines Market, by End-User, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cancer Vaccines Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Vaccines Market Dynamics

  • 3.1. Cancer Vaccines Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Cancer Vaccines Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Vaccines Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Cancer Vaccines Market by Type, Performance - Potential Analysis
  • 5.3. Global Cancer Vaccines Market Estimates & Forecasts by Type 2017-2027 (USD Billion)
  • 5.4. Cancer Vaccines Market, Sub Segment Analysis
    • 5.4.1. Preventive Cancer Vaccines
    • 5.4.2. Therapeutic Cancer Vaccines

Chapter 6. Global Cancer Vaccines Market, by Technology

  • 6.1. Market Snapshot
  • 6.2. Global Cancer Vaccines Market by Technology, Performance - Potential Analysis
  • 6.3. Global Cancer Vaccines Market Estimates & Forecasts by Technology 2017-2027 (USD Billion)
  • 6.4. Cancer Vaccines Market, Sub Segment Analysis
    • 6.4.1. Dendritic Cells (DC) Cancer Vaccines
    • 6.4.2. Recombinant Cancer Vaccines
    • 6.4.3. Antigen/Adjuvant Cancer Vaccines
    • 6.4.4. Viral Vector & DNA Cancer Vaccines

Chapter 7. Global Cancer Vaccines Market, by Indication

  • 7.1. Market Snapshot
  • 7.2. Global Cancer Vaccines Market by Indication, Performance - Potential Analysis
  • 7.3. Global Cancer Vaccines Market Estimates & Forecasts by Indication 2017-2027 (USD Billion)
  • 7.4. Cancer Vaccines Market, Sub Segment Analysis
    • 7.4.1. Cervical Cancer
    • 7.4.2. Prostate Cancer
    • 7.4.3. Others

Chapter 8. Global Cancer Vaccines Market, by End-User

  • 8.1. Market Snapshot
  • 8.2. Global Cancer Vaccines Market by End-User - Potential Analysis
  • 8.3. Global Cancer Vaccines Market Estimates & Forecasts by End-User 2017-2027 (USD Billion)
  • 8.4. Cancer Vaccines Market, Sub Segment Analysis
    • 8.4.1. Paediatrics
    • 8.4.2. Adults

Chapter 9. Global Cancer Vaccines Market, Regional Analysis

  • 9.1. Cancer Vaccines Market, Regional Market Snapshot
  • 9.2. North America Cancer Vaccines Market
    • 9.2.1. U.S. Cancer Vaccines Market
      • 9.2.1.1. Type breakdown estimates & forecasts, 2017-2027
      • 9.2.1.2. Technology breakdown estimates & forecasts, 2017-2027
      • 9.2.1.3. Indication breakdown estimates & forecasts, 2017-2027
      • 9.2.1.4. End-User breakdown estimates & forecasts, 2017-2027
    • 9.2.2. Canada Cancer Vaccines Market
  • 9.3. Europe Cancer Vaccines Market Snapshot
    • 9.3.1. U.K. Cancer Vaccines Market
    • 9.3.2. Germany Cancer Vaccines Market
    • 9.3.3. France Cancer Vaccines Market
    • 9.3.4. Spain Cancer Vaccines Market
    • 9.3.5. Italy Cancer Vaccines Market
    • 9.3.6. Rest of Europe Cancer Vaccines Market
  • 9.4. Asia-Pacific Cancer Vaccines Market Snapshot
    • 9.4.1. China Cancer Vaccines Market
    • 9.4.2. India Cancer Vaccines Market
    • 9.4.3. Japan Cancer Vaccines Market
    • 9.4.4. Australia Cancer Vaccines Market
    • 9.4.5. South Korea Cancer Vaccines Market
    • 9.4.6. Rest of Asia Pacific Cancer Vaccines Market
  • 9.5. Latin America Cancer Vaccines Market Snapshot
    • 9.5.1. Brazil Cancer Vaccines Market
    • 9.5.2. Mexico Cancer Vaccines Market
  • 9.6. Rest of The World Cancer Vaccines Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Advaxis Inc.
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Amgen Inc.
    • 10.2.3. Dynavax Technologies Corporation
    • 10.2.4. Generex Biotechnology Corporation
    • 10.2.5. GlaxoSmithKline plc (GSK)
    • 10.2.6. Immunocellular Therapeutics, Ltd.
    • 10.2.7. Merck & Co., Inc.
    • 10.2.8. Sanpower Group Co. Ltd.
    • 10.2.9. UbiVac, Inc.
    • 10.2.10. Vaccinogen, Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.